Similarly, treatment of CML CD34+ cells from patients in chronic phase or blast phase CML (all p53WT) with IDASA and/or NIL was effective at selectively increasing apoptosis and reducing CFC and LT-CIC outputs particularly when used in combination (Fig. 3c, d; Fig. S3b). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.